Serological Status of Epstein-Barr Virus in Bone Marrow Donor and Recipient and its Impact on Post-Transplant Outcomes
Author(s):
Ana Vitória Magalhães Chaves¹*, Hércules Amorim Mota Segundo², Sarah Emanuelle Viana Campos³, Karine Sampio Nunes Barroso4
and
Fernando Barroso Duarte4
The Epstein-Barr Virus (EBV) is a highly immunogenic herpesvirus that infects more than 90% of healthy individuals and can remain latent in B lymphocytes for years. In this context, in immunocompromised patients, such as those undergoing Bone Marrow Transplantation (BMT), viral reactivation can occur in up to 63% of cases. Among the main risk factors for viral reactivation are donor-recipient incompatibility, EBV IgG-positive donors, and conditioning regimens using lymphodepleting drugs such as anti-thymocyte immunoglobulin, high-dose cyclophosphamide, and corticosteroids. Therefore, weekly EBV monitoring is recommended during the first 100 days post-transplant to detect viremia early and enable preemptive intervention, either by reducing immunosuppression or using anti-CD20 monoclonal antibodies. These strategies aim to reduce viremia progression and the incidence of Post-Transplant Lymphoproliferative Disease (PTLD). This study seeks to estimate the serological profile of bone marrow donors and recipients and its relationship with the incidence of post-BMT viral reactivation. Additionally, it aims to evaluate monitoring and preemptive treatment strategies for managing high-risk patients at the Walter Cantídio University Hospital from 2020 to 2024, while also defining the incidence of PTLD secondary to BMT.
